Global Information
회사소개 | 문의 | 비교리스트

땅콩 알레르기 : 파이프라인 리뷰

Peanut Allergy - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 251569
페이지 정보 영문 158 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


땅콩 알레르기 : 파이프라인 리뷰 Peanut Allergy - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 158 Pages

땅콩 알레르기는 특히 어린이에게서 자주 볼 수 있습니다. 땅콩 알레르기 반응은 보통 섭취 후 몇 분 이내에 발생하며, 증상은 가벼운 것부터 심한 것까지 여러가지가 있습니다. 땅콩 알레르기의 징후 및 증상에는 입과 목 주변의 두드러기, 빨개지거나 부어오름, 가렵거나 따끔거림, 설사, 위경련, 메스꺼움, 구토 등 소화기관의 문제 발생, 호흡 곤란, 쌕쌕거리는 호흡, 콧물 등이 있습니다.

땅콩 알레르기(Peanut Allergy) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업이나 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 전해드립니다.

서론

  • 조사 범위

땅콩 알레르기 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

기업에서 개발중인 치료제

대학 및 연구기관에서 연구중인 치료제

파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명확한 제품

기업에서 개발중인 제품

대학 및 연구기관에서 연구중인 제품

치료제 개발에 참여하고 있는 기업

  • BioLingus AG
  • BioTech Tools s.a.
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • aldesleukin
  • Allergen for Peanut Allergy
  • AR-101
  • ARA-LAMP-Vax
  • DBV-712
  • DN-1017
  • Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma
  • Drugs to Inhibit PIM-1 Kinase for Respiratory and Immunological Diseases
  • PER-1080
  • pnut-ASIT
  • Recombinant Protein for Peanut Allergy
  • Recombinant Vector Vaccine for Peanut Allergy
  • VTC-064

최근의 파이프라인 동향

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 16.01.08

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Peanut Allergy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Peanut Allergy - Pipeline by Adverum Biotechnologies Inc, H1 2020
  • Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, H1 2020
  • Peanut Allergy - Pipeline by Allakos Inc, H1 2020
  • Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H1 2020
  • Peanut Allergy - Pipeline by AnaptysBio Inc, H1 2020
  • Peanut Allergy - Pipeline by Aravax Pty Ltd, H1 2020
  • Peanut Allergy - Pipeline by ASIT Biotech SA, H1 2020
  • Peanut Allergy - Pipeline by Astellas Pharma Inc, H1 2020
  • Peanut Allergy - Pipeline by BioLingus AG, H1 2020
  • Peanut Allergy - Pipeline by BlueWillow Biologics Inc, H1 2020
  • Peanut Allergy - Pipeline by Cambridge Allergy Ltd, H1 2020
  • Peanut Allergy - Pipeline by Cour Pharmaceuticals Development Co Inc, H1 2020
  • Peanut Allergy - Pipeline by DBV Technologies SA, H1 2020
  • Peanut Allergy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Peanut Allergy - Pipeline by HAL Allergy BV, H1 2020
  • Peanut Allergy - Pipeline by Inimmune Corp, H1 2020
  • Peanut Allergy - Pipeline by InnoUp Farma SL, H1 2020
  • Peanut Allergy - Pipeline by Moonlight Therapeutics Inc, H1 2020
  • Peanut Allergy - Pipeline by ProTA Therapeutics Pty Ltd, H1 2020
  • Peanut Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Peanut Allergy - Pipeline by Sementis Ltd, H1 2020
  • Peanut Allergy - Pipeline by Vedanta Biosciences Inc, H1 2020
  • Peanut Allergy - Pipeline by Virtici LLC, H1 2020
  • Peanut Allergy - Pipeline by ZENII LLC, H1 2020
  • Peanut Allergy - Dormant Projects, H1 2020
  • Peanut Allergy - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Peanut Allergy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H1 2020, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 6, 3, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 2 and 1 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Peanut Allergy - Overview
  • Peanut Allergy - Therapeutics Development
  • Peanut Allergy - Therapeutics Assessment
  • Peanut Allergy - Companies Involved in Therapeutics Development
  • Peanut Allergy - Drug Profiles
  • Peanut Allergy - Dormant Projects
  • Peanut Allergy - Discontinued Products
  • Peanut Allergy - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q